Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

NCT05532696 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Non Small Cell Lung Cancer
HER2 Mutations

Interventions

DRUG: ABT-101

Sponsor

Anbogen Therapeutics, Inc.